Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza virus vaccine - Seqirus

Next Previous
Drug Profile

Influenza virus vaccine - Seqirus

Alternative Names: Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc); FLUCELVAX; Flucelvax; Flucelvax Pediatric; FLUCELVAX QUAD; FLUCELVAX QUADRIVALENT; Flucelvax TETRA; Influenza vaccine (Flucelvax); Influenza vaccine (prepared in cell culture) - Seqirus; Optaflu; QIVc; TIVc

Latest Information Update: 29 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Seqirus
  • Class Influenza virus vaccines; Subunit vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 29 Jan 2026 No development reported - Phase-III for Influenza virus infections (In children, In infants, Prevention) in Pakistan (IM)
  • 29 Jan 2026 No development reported - Phase-III for Influenza virus infections (Prevention, In infants, In children) in South Africa (IM)
  • 17 Oct 2024 The CHMP of the EMA recommends approval of influenza virus vaccine for Influenza virus infections (Prevention, In children, In adults) in the EU

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top